Dermatomycosis is a type of skin disease majorly caused by the
infection of different species of dermatophytes, yeast such as
Candida species and Malassezia furfur or variety of fungi species
like microsporum, genera trichophyton and epidermophyton. These
organisms invade into the layer of skin and affect dermal appendices
of hair, nails and epidermis. The condition is mainly characterized
by colonization of the keratinized layers by these organisms on the
surface of patient’s skin.
Request Report Brochure @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=33965
These organisms have rigid cell wall and are complex in structure
thus, anti-bacterial agents are not effective against organisms.
Anti-dermatomycosis skin drugs like ketoconazole, clotrimazole and
others are effectively used for the treatment of infection. These
drugs are commonly used to treat conditions like ringworm, athlete’s
foot and other systemic fungal infections like cryptococcal
meningitis, and other types of infections. In addition, physical
examination and microscopic examination of dermal lesions can be
helpful to detect the disease condition.
The market of anti-dermatomycosis skin drugs is witnessing positive
growth owing to the rise in fungal infections cases globally. World
Health Organization (WHO) stated that nearly 20% of the world
population is suffering from skin infections and the percentage is
even higher in subtropical or tropical areas. In addition, good
penetration and distribution of these drugs into hair folicles and
horny layers will offer effective treatment in skin infection
disorders and hence drives the market growth of anti-dermatomycosis
skin drugs. However, less specific actions of anti-fungal drugs
restrains the growth of global anti-dermatomycosis skin drugs market.
In addition, high rate of side-effects like nausea, vomiting,
constipation, hepatitis will restrain the market of
anti-dermatomycosis skin drugs. In severe condition, adverse effects
like renal toxicity, hypokalaemia, hepatic failure, anaphylactic
shock can be developed. Thus, high rate of adverse effects, using
these drugs will restrain the market growth of anti-dermatomycosis
skin drugs. Additionally, high cost coupled with high rate of
unwanted drug interactions of drugs will further restraint the market
growth.
Enquiry for discount on this report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=33965
Geographically, North America dominates the global
anti-dermatomycosis skin drugs market. The growth of this market in
North America is mainly attributed to increase incidence of skin
infections. Europe is considered as the second largest region for
global anti-dermatomycosis skin drugs market owing to increasing use
of anti-dermatomycosis drugs. The market of anti-dermatomycosis skin
drugs in Asia-Pacific region holds strong growth opportunities due to
favorable climate condition for the development of skin infectious
organisms.
This factor would ultimately increase the number of patients seeking
for the treatment of skin infections hence drives the market growth
of anti-dermatomycosis skin drugs market. Additionally, countries
like China and India are considered as the major market for
anti-dermatomycosis skin drugs market owing to the high demand of
these drugs among patient population which will eventually help
Asia-Pacific region to grow steadily.
The market of anti-dermatomycosis skin drugs is majorly dominated by
the key players like Amplyx Pharmaceuticals, Inc., Vectura Group plc,
Pfizer, Inc., AstraZeneca PLC, Eli Lilly and Company, Aparna
Biosciences Corporation, Helix BioMedix, Inc., Aegera Therapeutics,
Inc., Globeimmune, Inc. and others.
Report Overview @
https://www.transparencymarketresearch.com/antidermatomycosis-skin-drugs-market.html
About Us
Transparency Market Research is a next-generation market intelligence
provider, offering fact-based solutions to business leaders,
consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow,
evolve, and mature. Our real-time data collection methods along with
ability to track more than one million high growth niche products are
aligned with your aims. The detailed and proprietary statistical
models used by our analysts offer insights for making right decision
in the shortest span of time. For organizations that require specific
but comprehensive information we offer customized solutions through
adhoc reports. These requests are delivered with the perfect
combination of right sense of fact-oriented problem solving
methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems
with right methodology of research is the key to help enterprises
reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment